|
miRNA | Type of DM | Study design | Study population | Profiling | Source | Significant comparisons-details | Reference |
|
Diabetes microvascular complications |
↑ 661 ↑ 571 ↑ 770-5p ↑ 892b ↑ 1303 | DM2 | Case Control | DMC+ () DMC− () Controls () | Yes | Serum | DM versus controls DMC+ versus DMC− | [110] |
↑ 31 | DM2 | Case Control | DMC () DM-CVD () DM () | Yes | Serum | DMC versus others | [111] |
Diabetic retinopathy |
↓ 27b ↑ 320a | DM1 | Nested Case Control | Incidence of DR () Progression of DR () Controls () | Yes | Serum | 27b: OR: incidence of DR 0.57 (0.40, 0.82); 320: OR: incidence of DR 1.57 (1.07, 2.31), OR: progression of DR 1.43 (1.05, 1.94) | [112] |
↓ 126 | DM1 | Nested Case Control | Complications+ () Complications− () | Yes | Serum | OR: PDR 0.75 (0.59–0.95) | [113] |
↑ 21 ↑ 181c ↑ 1179 | DM2 | Case Control | PDR () NPDR () Controls () | Yes | Serum | PDR versus NPDR | [115] |
↓ 126 | DM2 | Case Control | PDR () NPDR () DR− () Controls () | No | Serum | PDR versus DR− | [114] |
↑ 93 | DM2 | Case Control | DR+ () DR− () Controls () | No | Plasma | DR+ versus DR− | [117] |
↑ 21 | DM2 | Case Control | PDR () NPDR () DR− () Controls () | No | Plasma | PDR and NPDR versus DR− | [116] |
↑ 23a ↑ 320a-b | DM2 | Case Control | PDR () ME () | Yes | Vitreous/ serum | PDR versus ME | [138] |
Diabetic nephropathy |
↓ let-7c ↓ 29a ↑ let-7b ↑ 21 | DM1 | Prospective: rapid progression to ESRF | Macro RP () Macro NP () Normo () | No | Plasma | let-7c: OR: 0.23 (0.10, 0.53) 29a: OR: 0.39 (0.20, 0.76) let-7b: OR: 2.38 (1.31, 4.0) 21: OR: 5.87 (1.68, 20.46) | [118] |
↑ 217 | DM2 | Case Control | Normo () Micro () Macro () Controls () | No | Serum | DM2 versus controls Micro versus normo Macro versus micro | [121] |
↑ 21 ↑ 29a ↑ 192 | DM2 | Case Control | Macro () Micro () Normo () | No | Serum | Macro versus micro and normo CKD+ (n = 18) versus CKD− (n = 32) | [120] |
↓ 130 | DM2 | Case Control | Normo () Micro () Macro () Controls () | No | Serum | Macro versus micro and normo Micro versus normo Controls versus others | [123] |
↓ let-7a | DM2 | Case Control | DN− () DN+ () Controls () | Yes | Blood | DN+ versus DN− | [119] |
↓ 126 | DM2 | Case Control | Normo () DM2-micro (n = 29) DM2-macro () Controls () | No | Blood | Micro-macro versus controls and normo Macro versus micro | [122] |
Urinary miRNA in diabetic nephropathy |
↓ 15 | DM2 | Case Control | CKD-IgAN () CKD-DN () CKD-HTN () | Yes | Urinary sediment | DN versus others CKD | [124] |
↓ 192 | DM2 | Case Control | DN () MCN/FGS () MGN () Controls () | No | Urinary sediment | DN versus others | [125] |
↓ 2861 ↓ 1915-3p ↓ 4532 | DM2 | Case Control | DN+ () DN− () | Yes | Urine | DN+ versus DN− | [126] |
↓ 323b-5p ↑ 122-5p ↑ 429 | DM1 | Case Control | Normo () Intermittent micro () Persistent micro () Macro () | Yes | Urine | Persistent versus intermittent micro | [127] |
105, 1972, 28, 30b, 363, 424, 486, 495, 548o | DM1 | Prospective: micro onset | Normo () | Yes | Urine | 9 miRNAs: molecular miRNA signature for microalbuminuria | [128] |
29a | DM2 | Case Control | Macro/micro () Normo () | No | Urine | Macro/micro versus normo | [139] |
↑ 130a ↑ 145 ↓ 155 ↓ 424 | DM1 | Case Control | Micro () Normo () | Yes | Urinary exosomes | Micro versus normo | [129] |
↑ 320c ↑ 6068 | DM2 | Case Control | DN+ () DN− () Controls () | Yes | Urinary exosomes | DN+ versus DN− and controls | [130] |
↑ 133b ↑ 342 ↑ 30a | DM2 | Case Control | Macro () Micro () Normo () Controls () | No | Urinary exosomes | Macro and micro versus normo (133b only macro versus micro) | [131] |
↑ 192 ↑ 194 ↑ 215 | DM2 | Case Control | Normo () Micro () Macro () Controls () | No | Urinary MV | Micro versus normo, controls, and macro | [132] |
|